tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Developments and Revenue Prospects Reinforce Buy Rating for Ligand Pharma
PremiumRatingsPromising Developments and Revenue Prospects Reinforce Buy Rating for Ligand Pharma
2M ago
Ligand Pharma’s Strong Financial Outlook and Strategic Investments Justify Buy Rating
Premium
Ratings
Ligand Pharma’s Strong Financial Outlook and Strategic Investments Justify Buy Rating
3M ago
Ligand price target raised to $230 from $220 at Stifel
Premium
The Fly
Ligand price target raised to $230 from $220 at Stifel
3M ago
Ligand to host 2025 Investor Day
PremiumThe FlyLigand to host 2025 Investor Day
3M ago
Ligand reiterates 2025 core adjusted EPS view $7.40-$7.65, consensus $7.62
Premium
The Fly
Ligand reiterates 2025 core adjusted EPS view $7.40-$7.65, consensus $7.62
3M ago
Ligand Pharma’s Strategic Positioning and Growth Prospects Justify Buy Rating
Premium
Ratings
Ligand Pharma’s Strategic Positioning and Growth Prospects Justify Buy Rating
3M ago
Ligand price target raised to $220 from $195 at Stifel
PremiumThe FlyLigand price target raised to $220 from $195 at Stifel
4M ago
Ligand price target raised to $220 from $175 at Benchmark
Premium
The Fly
Ligand price target raised to $220 from $175 at Benchmark
4M ago
Ligand price target raised to $275 from $250 at Oppenheimer
Premium
The Fly
Ligand price target raised to $275 from $250 at Oppenheimer
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100